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Introduction {#jmrs376-sec-0005}
============

In the last decade, there has been a rise in the incidence of oropharyngeal carcinoma. This rise has been attributed to the increased incidence of human papilloma virus (HPV)‐related cancers.[1](#jmrs376-bib-0001){ref-type="ref"}, [2](#jmrs376-bib-0002){ref-type="ref"} HPV‐related cancers are highly responsive to treatment, with improved disease‐specific and overall survival.[3](#jmrs376-bib-0003){ref-type="ref"} Combined chemoradiotherapy has become the preferred treatment option for these patients, with a 3‐year overall survival rate of 82.4%.[3](#jmrs376-bib-0003){ref-type="ref"}, [4](#jmrs376-bib-0004){ref-type="ref"} In view of their excellent response to treatment and prolonged survival, a major focus is on reducing treatment morbidity by improving treatment techniques and doses to organs at risk (OARs).

Previous studies have reported on significant improvements in survival as well as reduced toxicity in head and neck cancer patients treated with inversely planned radiation therapy.[4](#jmrs376-bib-0004){ref-type="ref"}, [5](#jmrs376-bib-0005){ref-type="ref"} However, the radiotherapy planning process for these complex head and neck treatments is intensive and can create workflow issues within departments. Differences in staff experience and knowledge lead to variability in plan quality, with more experienced staff having a higher success at manipulation of planning objectives and priorities based on individual patient tumour size and proximity to OARs.[6](#jmrs376-bib-0006){ref-type="ref"}, [7](#jmrs376-bib-0007){ref-type="ref"} Furthermore, randomised studies have also shown a benefit of standardised plan analysis to improve plan quality and patient outcomes.[8](#jmrs376-bib-0008){ref-type="ref"} In an effort to address these challenges, there has been increasing interest in semi‐automated knowledge‐based planning (KBP) strategies. KBP tools such as RapidPlan™ (RP) have the potential to not only improve workflow but also improve plan quality.

Duke University[9](#jmrs376-bib-0009){ref-type="ref"}, [10](#jmrs376-bib-0010){ref-type="ref"}, [11](#jmrs376-bib-0011){ref-type="ref"}, [12](#jmrs376-bib-0012){ref-type="ref"}, [13](#jmrs376-bib-0013){ref-type="ref"} and Washington University[14](#jmrs376-bib-0014){ref-type="ref"}, [15](#jmrs376-bib-0015){ref-type="ref"} were the early innovators of KBP, providing evidence of increased consistency and plan quality. With the use of recently developed commercial knowledge‐based software, others have since focused on the predictability and reliability of such strategies, and the number of patients needed in each model to establish optimal outcomes.[16](#jmrs376-bib-0016){ref-type="ref"}

RapidPlan™ is the commercial KBP software released by Varian Medical Systems (Palo Alto, USA). The software auto‐creates line objectives for various OARs based on data uploaded to the system from the plans of previously treated patients.

Our study evaluates the resultant doses to the parotid glands for oropharyngeal radiotherapy planning through the use of the RP software, comparing two different knowledge‐based Oropharynx models. The first model, known as the 'separated model', contains parotid dose data from previously treated patients separated into contralateral and ipsilateral, while the second model, known as the 'combined model', combines the parotid data as one structure called 'parotids'. Fogliata et al[17](#jmrs376-bib-0017){ref-type="ref"} also investigated this comparison in a recent study and found that there was little difference between the two models for the resultant parotid dose. This current study sought to further validate this technique.

Methods {#jmrs376-sec-0006}
=======

Patient selection for RP model creation {#jmrs376-sec-0007}
---------------------------------------

A RP model requires a library to be created from the treatment plans of previously treated patients. Patients used in this study were obtained from the ethics approved head and neck database (NSLHD reference: RESP/15/255) and had undergone definitive radiotherapy for T1‐4, N0‐3 oropharyngeal SCC. A cohort of seventy patients was uploaded to the model, with the primary tumour locations including tonsil (*n* = 38), base of tongue (*n* = 29) and pharynx (*n* = 3).

Patients had been treated using a standard departmental protocol consisting of a simultaneous integrated boost (SIB) with a 6 MV dual arc VMAT technique. The prescription dose was 70 Gy in 35 fractions to the high‐risk volume, 63 Gy in 35 fractions to the intermediate‐risk volume and 56 Gy in 35 fractions to the prophylactic lymph node volume.

The higher dosed overlapping planning target volumes (PTV) were removed from the lower dosed PTVs creating cropped PTVs (cPTV), making it easier to assess the outliers using the RP model configuration statistics.

RP model configuration {#jmrs376-sec-0008}
----------------------

The plans and matched contours of the 70 patients were exported from the Eclipse planning system (version 13.6) to RP model configuration for subsequent training. These data were used to train the model, generating mathematical parameters through the analysis of the geometric and dosimetric statistics of the 70 uploaded patients plans and contours.

The separated model was created first. The OARs trained for this model included the ipsilateral parotid, contralateral parotid, larynx, spinal cord, spinal cord planning risk volume (PRV), brainstem and mandible. Determining the ipsilateral parotid was a manual process and was considered to be the side the high‐risk volume favoured. The opposite parotid was trained as contralateral parotid.

Model verification using model analytics {#jmrs376-sec-0009}
----------------------------------------

The Oropharynx model was then exported to Model Analytics (MA), a cloud‐based Varian endorsed programme on the MyVarian website, providing statistics of potential outlying plans, contours and dose volume histograms (DVH\'s) that would potentially decrease the integrity of the model. The results from the programme were assessed by reviewing each contour that the report highlighted in the clinical plan and removing it from the model if it was deemed to be an outlier that would degrade the quality of the model.

The RP statistics were then assessed to view any potential outliers missed in the previous steps. Again, any contours that were highlighted as outliers in the RP statistics were viewed in the plan and removed from the model if they were deemed to be an outlier.

Upper, lower and line objectives and priorities were then created in model configuration for each target and OAR that aimed to achieve the standard departmental protocol objectives. The cPTV\'s were used for the optimisation process. The gross tumour volume (GTV) structure (GTV Primary volume/GTV Primary Volume + GTV Nodal Volume) was also removed from cPTV high dose (cPTV HD) creating optimising PTV HD (oPTV HD). The GTV and oPTV HD were attached to the PTV HD objectives and priorities for the DVH estimation process. After the optimising values had been generated, optimisation objectives (see Table [1](#jmrs376-tbl-0001){ref-type="table"}) were added to these structures manually to ensure adequate coverage.

###### 

Manual optimisation objectives.

  Structure   Type    Dose (%)   Priority
  ----------- ------- ---------- ----------
  GTV         Upper   102.5      80
  GTV         Lower   102        100
  CTV HD      Lower   101        80
  CTV ID      Lower   102        80
  CTV LD      Lower   102        80

CTV = clinical target volume; GTV = gross tumour volume; HD = high dose; ID = intermediate dose; LD = low dose.

John Wiley & Sons, Ltd

For the serial organs or PRVs of these structures, where maximum constraints were the only constraint in the departmental protocol, a fixed upper objective and priority was used. For the larynx and parotids, where the accepted dose was more influenced by geometric factors, a generated line objective and priority was added. Tuning structures such as shoulders were contoured, and optimising objectives were attached as previously done before RP was introduced to our centre (see Table [2](#jmrs376-tbl-0002){ref-type="table"} for an overview of optimising values).

###### 

Model optimisation objectives.

  Target/Organ            Objective   Volume (%)   Dose (cGy or % of the specific target prescription)   Priority
  ----------------------- ----------- ------------ ----------------------------------------------------- -----------
  PTV HD                  Upper       0            101.7                                                 100
  Lower                   100         100.7        100                                                   
  PTV ID                  Upper       0            102.4                                                 100
  Lower                   100         100.8        100                                                   
  PTV LD                  Upper       0            102.7                                                 100
  Lower                   100         100.9        100                                                   
  GTV                     Upper       0            101.7                                                 100
  Lower                   100         100.7        100                                                   
  Larynx                  Line        Generated    Generated                                             Generated
  Mandible                Upper       0            6850                                                  80
  Contralateral parotid   Line        Generated    Generated                                             Generated
  Ipsilateral parotid     Line        Generated    Generated                                             Generated
  Spinal cord             Upper       0            3500                                                  75
  Spinal cord PRV         Upper       0            3800                                                  75
  Shoulders               Upper       0            500                                                   50

GTV = gross tumour volume; HD = high dose; ID = intermediate dose; LD = low dose; PTV = planning target volume.

John Wiley & Sons, Ltd

To create the two different models, the separated model was then duplicated. For each plan in the combined model, the parotids were adjusted from contralateral and ipsilateral, to one title called 'Parotids', which combined these data. The data were extracted again, and the model retrained with a generated line objective priority to be created for this one parotid structure for the optimising process. Figure [1](#jmrs376-fig-0001){ref-type="fig"}A--C are examples of the DVH data used by the model to estimate the parotids for both models and shows the difference in the DVH statistics uploaded for the parotids in each model.

![(A) The DVH data exported to the separated model for the ipsilateral parotid. (B) The DVH contralateral parotid data exported to the separated model. (C) The DVH parotid data for the combined model, a combination of the ipsilateral and contralateral DVH data from the separated model.](JMRS-67-80-g001){#jmrs376-fig-0001}

Model validation {#jmrs376-sec-0010}
----------------

To validate and compare the two models, a cohort of 20 oropharynx patients not used in the creation of the library was optimised once using both models. The templated manual optimising objectives were added after the models had been attached but before commencing the optimising process. There was no more human interaction after the commencement of the optimisation. The resulting parotid mean and V50 doses were compared as these are the parameters assessed in the clinical setting. PTV coverage was also assessed to determine whether the models were producing clinically treatable plans.

Results {#jmrs376-sec-0011}
=======

During the validation process, the contours of 16 structures (10 larynxes, 5 ipsilateral parotids and 1 contralateral parotid) were removed as they were deemed to degrade the quality of the model. No whole plans were removed during the MA and RP statistic processes. The contours included in the model and the number of each OAR contour that remained after the validation process are presented in Table [3](#jmrs376-tbl-0003){ref-type="table"}.

###### 

Number of contour structures within each of the RP models.

  Combined model    Separated model                           
  ----------------- ----------------- ----------------------- ----
  PTV HD            70                PTV HD                  70
  PTV ID            70                PTV ID                  70
  PTV LD            70                PTV LD                  70
  GTV               70                GTV                     70
  Parotid           134               Ipsilateral parotid     65
                                      Contralateral parotid   69
  Spinal cord       70                Spinal cord             70
  Spinal cord PRV   70                Spinal cord PRV         70
  Larynx            60                Larynx                  60
  Brainstem         45                Brainstem               45
  Mandible          40                Mandible                40

GTVp = gross tumour volume primary; HD = high dose; ID = intermediate dose; LD = low dose; PTV = planning target volume.

John Wiley & Sons, Ltd

*Plan comparison:* Plans were produced successfully using both models on all 20 validation patients. Table [4](#jmrs376-tbl-0004){ref-type="table"} contains the characteristics of all 20 validation patients. Both models achieved departmental protocol for minimum PTV coverage for all 20 validation patients which were 95% of the prescribed dose covering 95% of the PTV volume. Table [5](#jmrs376-tbl-0005){ref-type="table"} gives an overview of the doses the OARs received from the two models.

###### 

Patient characteristics.

  Patient   ICD‐O site       Staging   Laterality   GTV vol (cc)   CTV vol (cc)
  --------- ---------------- --------- ------------ -------------- --------------
  1         Tonsil           T3N2b     Left         6.9            51.7
  2         Base of tongue   T4aN2c    Right        6.3            28.6
  3         Base of tongue   T2N1      Right        2.1            29.0
  4         Base of tongue   T2N2a     Right        12.7           93.0
  5         Tonsil           T3N2c     Right        12.2           82.5
  6         Base of tongue   T1N2b     Right        2.6            94.8
  7         Base of tongue   T1N2b     Right        3.3            27.8
  8         Tonsil           T4bN3     Left         2.4            189.8
  9         Base of tongue   T1N1      Left         3.0            35.0
  10        Tonsil           T1N2a     Left         2.2            55.7
  11        Base of tongue   T2N2b     Right        4.9            39.6
  12        Tonsil           T3N2c     Left         14.3           65.3
  13        Base of tongue   T3N2b     Right        28.5           68.8
  14        Base of tongue   T3N2a     Right        31.7           86.8
  15        Tonsil           T4aN1     Right        20.2           53.8
  16        Base of tongue   T1N2b     Right        22.1           99.2
  17        Base of tongue   T1N3      Left         1.9            146.0
  18        Base of tongue   T3N2b     Right        20.3           56.4
  19        Tonsil           T1N3      Left         9.0            104.9
  20        Tonsil           T2N0      Right        14.0           42.5

John Wiley & Sons, Ltd

###### 

OAR doses (Gy).

  OAR              Model        Dose range   Mean dose   V50    Max (avg.)
  ---------------- ------------ ------------ ----------- ------ ------------
  Ipsi parotid     Combined     0--75.3      33.8        32.4   70.5
  Separated        0--74.5      35.5         34.2        70.2   
  Contra parotid   Combined     1.8--74.6    19.8        15.7   59.2
  Separated        1.9--75.0    20.5         15.4        59.7   
  Spinal cord      Combined     0.1--43.9    27.5        34.2   41.9
  Separated        0.1--44.3    27.5         34.0        42.1   
  Larynx           Combined     13.8--74.2   33.9        32.9   57.1
  Separated        14.4--71.2   33.9         32.9        57.3   

John Wiley & Sons, Ltd

Average DVH curves comparing the two models for contralateral and ipsilateral parotid doses are shown in Figures [2](#jmrs376-fig-0002){ref-type="fig"}A and B. The combined model and separated model produced very similar contralateral parotid doses, but a lower ipsilateral parotid mean dose was seen in 16 of the 20 cases (average difference 1.8 Gy) and lower contralateral parotid doses in 11 of the 20 cases.

![(A) Average contralateral parotid DVH for each model. (B) Average ipsilateral parotid DVH for each model.](JMRS-67-80-g002){#jmrs376-fig-0002}

Discussion {#jmrs376-sec-0012}
==========

With excellent survival outcomes in patients with oropharyngeal cancers,[3](#jmrs376-bib-0003){ref-type="ref"}, [4](#jmrs376-bib-0004){ref-type="ref"} improved radiation treatment techniques are important to prevent long‐term treatment‐related toxicity. Using Varian\'s KBP software RP, two models using 70 previously treated patients with Oropharyngeal SCC were developed. Results from our study indicate no benefit for the contralateral parotid in separating parotid data into ipsilateral and contralateral when constructing models, with a potential improvement in ipsilateral doses. This is similar to results from Fogliata et al[17](#jmrs376-bib-0017){ref-type="ref"} who also found little difference in the parotid doses between models. There were also no significant trade‐offs between the results of the OAR\'s produced by both models which can be seen in Table [5](#jmrs376-tbl-0005){ref-type="table"}.

In our centre, planning staff have historically placed less importance on the optimisation of the ipsilateral parotid, with the belief that once the dose exceeds tolerance, there is no substantial benefit in small improvements in dose. Zhang et al[18](#jmrs376-bib-0018){ref-type="ref"} and Ren et al[19](#jmrs376-bib-0019){ref-type="ref"} explain the importance of parotid sparing to negate the potential for shrinkage and medial migration of the glands during treatment increasing dose. Keeping the dose to the parotids as low as possible has been shown to have a direct impact on the development of xerostomia, functional recovery of the glands and quality of life. By including the optimised contralateral parotid DVH data in the model, RP has increased quality data to use for the optimisation process which explains the improved ipsilateral doses.

The results of the study reinforce the notion that it is important to have quality plans within a model for it to utilise when estimating optimisation values for structures. Optimal plans used in models should have a positive influence on the results of RP models as was seen with the ipsilateral parotid results.

This concept may have ramifications for other RP models and may help in designing model construction. The concept of combining duplicate structures in models could be explored for other organs depending on tumour location, with the potential for similar outcomes. Examples of such organs are the hippocampus for models designed for central nervous system (CNS) treatment and kidneys for treatments in the abdomen.

It is also an easier and neater process for model creation when data for duplicate structures are involved. Having a single structure that corresponds to both parotids will result in less user error when creating a model or during the optimising of a plan where structures are attached to their corresponding structure in the model.

Conclusion {#jmrs376-sec-0013}
==========

Separation of the parotids into ipsilateral and contralateral in models, matching the goals of planning, did not improve parotid results. Combining the parotids resulted in lower estimations for the ipsilateral parotid and therefore lower doses. The outcomes may influence the designing of similar models with duplicate structures.
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